<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608087</url>
  </required_header>
  <id_info>
    <org_study_id>1302.1</org_study_id>
    <nct_id>NCT01608087</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish
      pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</measure>
    <time_frame>up to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma</measure>
    <time_frame>up to 99 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 695502</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of BI 695502</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one i.v. infusion of bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one i.v. infusion of bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 695502</intervention_name>
    <description>BI 695502 single i.v. infusion</description>
    <arm_group_label>BI 695502</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>bevacizumab single i.v. infusion</description>
    <arm_group_label>bevacizumab B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>bevacizumab single i.v. infusion</description>
    <arm_group_label>bevacizumab A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males.

          2. Complete medical history, including physical examination, vital signs, 12-lead
             electrocardiogram (ECG), and clinical laboratory tests.

          3. Aged 21 to 50 years.

          4. Body mass index below or equal to 30.

          5. Body weight 65 to 95 kg, inclusive.

        Exclusion criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance.

          2. Any evidence of a clinically relevant concomitant disease, as judged by the
             investigator.

          3. History of relevant orthostatic hypotension, fainting spells, or blackouts.

          4. Chronic or relevant acute infections.

          5. History of relevant allergy/hypersensitivity (including allergy to the study
             medications or its excipients).

          6. Intake of prescribed or over-the-counter drugs within less than 6 half-lives of the
             respective drug prior to study drug administration or during the trial.

          7. Participation in another trial with a study medication within two months prior to
             administration or during the trial (six half-lives).

          8. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day).

          9. Inability to refrain from smoking during days of confinement at the study center.

         10. Current alcohol abuse as judged by the investigator.

         11. Current drug abuse, as judged by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1302.1.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1302.1.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

